Fundraising FoxLongitude Capital — 2018 Investments
8 investments dated 2018 · listed companies and verified rows first · show all
CuraSen Therapeutics is a privately funded biopharmaceutical company developing treatments that selectively activate adrenergic receptors in the brain to restore noradrenergic signaling.
BiotechHealthtechSan Carlos, US
Anthony Ford(Executive Officer, Director)inBenjamin Potter(Executive Officer)Henry Skinner(Director)Liam Ratcliffe(Director)in
BoardRon Hunt(Director)inLoretta Tse, Ph.D.(Director)
Co-investorsAlta Partnersabrdn plcIntermediate Capital GroupJohnson & Johnson Innovation – JJDCNew Leaf Venture PartnersPappas Capital+2 more
Eargo was a hearing aid company that provided high-quality hearing aids and related care services.
HealthtechMedical DevicesMountain View, US
Raphael Michel(Founder)Christian Gormsen(Executive Officer, Director)William Brownie(Executive Officer)Peter Tuxen Bisgaard(Director)Daniel Shen(Founder)Florent Michel(Founder)
Co-investorsBirchmere VenturesDolby Family VenturesMaveronNew Enterprise Associates (NEA)Peterson VenturesCrosslink Capital+4 more
Murj provides a software platform for cardiac clinics, tailoring its solution to each clinic's specific workflows and challenges.
Digital HealthHealthtechMedical DevicesSaaSSanta Cruz, US
Patrick Beaulieu(Founder)inTodd Butka(Founder)
BoardMark Bartell(Director)Reed Gaither(Co-founder)
Co-investorsTrue Ventures
BiotechDublin 1
Jennifer Schranz(Executive Officer)Axel Bolte(Director)Gary Sender(Executive Officer)Theodore Schroeder(Executive Officer, Director)Robert Crotty(Executive Officer)Colin Broom(Director)
Co-investorsAisling CapitalEcoR1 CapitalFrazier Life SciencesMESA VERDE VENTURE PARTNERSNovartis Venture Fund
Poseida Therapeutics develops cell therapy candidates and related platform technologies for healthcare applications.
BiotechHealthtechSan Diego, US
Eric Ostertag(Executive Officer, Director)Mark Gergen(Executive Officer, Director)
BoardAdrian Howd(Director)David Hirsch(Director)
Co-investorsAisling CapitalRapha Capital Management, LLCVivo Capital
BiotechCambridge, US
James G. McArthur(Executive Officer)Abraham N. Ceesay(Executive Officer)Christoph M. Adams(Executive Officer, Director)
BoardMette Kirstine Agger(Director)David Mott(Director)Sandip Agarwala(Director)
Co-investorsAlexandriaLundbeckfonden VenturesNew Enterprise Associates (NEA)
Biotechnology company developing products for overactive bladder and irritable bowel syndrome.
BiotechMalvern, US
Douglas Gessl(Executive Officer)inJames Walker(Executive Officer, Director)in
BoardScott Morenstein(Director)David Hirsch(Director)James Bennethum(Director)Stephen Tullman(Director)
Co-investorsFountain Healthcare PartnersSamsara BioCapital
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.